Theragnostic method for cancer patients

Abstract

A radiopharmaceutical composition is here described comprising as the active ingredient copper-64 in ionic form (64Cu++), in combination with suitable excipients, and/or diluents, having radioconcentration comprised between 50 and 3,500 MBq/mL at calibration time. Such radiopharmaceutical composition is useful in a method for treating a subject affected by a neoplasia. Such method may comprise a step for evaluating the eligibility of a patient for the treatment, in which 64Cu++ cellular uptake is detected. In case no uptake is detectable, the treatment is not advisable. In case radioactive copper uptake from cancer lesions is detectable, this has a predictive value of response to treatment and the subject is selected for the treatment. If the patient is eligible for the treatment and is selected for the treatment, the method further comprises a step of treating cancer in said subject by administering a therapeutically effective amount of the same 64Cu++ salt.

Dependencies are inferred from the claim text.